Accession Number:



Rational Therapies for Diffuse-Type Gastric Cancer

Descriptive Note:

Technical Report,15 Aug 2017,14 Aug 2019

Corporate Author:

The Regents of the University of California San Francisco United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Diffuse-type gastric cancer DGC is a devastating disease that is associated clinically with linitis plastic, which is characterized by diffuse infiltration of the gastric wall. Histologically, the DGC consists of cells displaying loss of hemophilic cell-cell interactions, signet-ring features and diffuse cell scattering into normal tissues. Symptoms occur late, frequently in form of early satiety resulting from cancer-related stiffness of the gastric wall. Clinical management of the disease is particularly challenging because it occurs significantly more frequently in younger patients compared to the intestinal type, does not respond well to chemotherapy and no effective targeted therapies are known. As a result of these factors, the prognosis for patients with the disease is poor the median survival for patients with DGC is 17 months after surgical resection with curative intent compared to 129 months for patients with intestinal type. Similarly, DGC has been found to be associated with poor response to neo-adjuvant chemotherapy. Thus, there is an urgent need for novel treatment approaches for this devastating disease.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: